Article
Efficacy and safety of first-line osimertinib in Chinese patients with EGFR-mutated advanced non-small cell lung cancer: a prospective, multicenter, non-interventional study (FLOURISH).
Cancer biology & medicine - 21 May 2026
Shen Lisha, Lv Dongqing, Tang Ke-Jing, Zhao Jun, Zhu Dan, Zhao Yanqiu, Wang Ke, Wang Yan, Cai Zhigang, Xing Ligang, Xie Ke, Cui Jiuwei, Mu Lin, Cao Chao, Ding Liren, Chen Peifeng, Liang Jun, Ding Yongmin, Lu Liqin, Zhang Jiliang, Yu Xinmin, Chen Li, Zheng Jing, Zhou Jianya, Zhou Jianying
Abstract excerpt
OBJECTIVE: Osimertinib has demonstrated superior efficacy as a first-line treatment for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) in clinical trials. This study was aimed at providing real-world evidence of osimertinib treatment in Chinese populations. METHODS: This prospective, multicenter, non-interventional study was conducted from July 27, 2020, to April 27, 2022....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.